CureVac NV (WBO:CVAC) Cash-to-Debt : 9.69 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is CureVac NV Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. CureVac NV's cash to debt ratio for the quarter that ended in Dec. 2023 was 9.69.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, CureVac NV could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for CureVac NV's Cash-to-Debt or its related term are showing as below:

WBO:CVAC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.41 Med: 20.07 Max: No Debt
Current: 9.69

During the past 6 years, CureVac NV's highest Cash to Debt Ratio was No Debt. The lowest was 0.41. And the median was 20.07.

WBO:CVAC's Cash-to-Debt is ranked better than
55.19% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs WBO:CVAC: 9.69

CureVac NV Cash-to-Debt Historical Data

The historical data trend for CureVac NV's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

CureVac NV Cash-to-Debt Chart

CureVac NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.41

44.05

28.25

11.89

9.69

CureVac NV Quarterly Data
	Dec18	Mar19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															11.89	15.08	13.42	11.10	9.69

Competitive Comparison of CureVac NV's Cash-to-Debt

For the Biotechnology subindustry, CureVac NV's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CureVac NV's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where CureVac NV's Cash-to-Debt falls into.

CureVac NV Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

CureVac NV's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	405.113	/	(5.005	+	36.819)
	=	9.69

CureVac NV's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	405.113	/	(5.005	+	36.819)
	=	9.69

CureVac NV (WBO:CVAC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

CureVac NV Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of CureVac NV's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CureVac NV (WBO:CVAC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (WBO:CVAC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

CVAC:USA CVAC:Mexico 1CVAC:Italy 0A9E:UK 5CV:Germany

Address

Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.curevac.com

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.